Rock Springs Capital Master Fund LP
SEC CIK 1735393 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | 10% | 1.26M | $8.00M | — | 2 | 2021-10-26 | 2021-10-26 |
Most active insiders at XLO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Shannon James Samuel | Dir | $43.9K | — |
| 2 | Frankenfield Christopher James | CFO | — | $4,499 |
| 3 | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | — | $1,169 |
| 4 | Luptakova Katarina | Chief MEDICAL Off | — | — |
| 5 | Russo Rene | Pres AND CEO, Dir | — | — |
Rock Springs Capital Master Fund LP made no open-market trades at XLO in the last 12 months.
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2021-10-26 | 2021-10-26 | XLO | Xilio Therapeutics, Inc. | Rock Springs Capital Master Fund LP | 10% | P - Purchase | $16.00 | +500.0K | 1.26M | +66% | +$8.00M |
| DMI | 2021-10-26 | 2021-10-26 | XLO | Xilio Therapeutics, Inc. | Rock Springs Capital Master Fund LP | 10% | C - Cnv Deriv | — | +907.8K | 756.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations